Congress Park Capital LLC Sells 251,418 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Congress Park Capital LLC lessened its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 20.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 964,590 shares of the biotechnology company’s stock after selling 251,418 shares during the period. Congress Park Capital LLC owned 1.23% of CytomX Therapeutics worth $994,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CTMX. FMR LLC increased its position in shares of CytomX Therapeutics by 17.3% during the third quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock worth $335,000 after acquiring an additional 41,949 shares during the period. Geode Capital Management LLC grew its stake in CytomX Therapeutics by 4.4% in the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after purchasing an additional 34,032 shares in the last quarter. XTX Topco Ltd increased its holdings in CytomX Therapeutics by 382.6% during the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 48,033 shares during the period. Cubist Systematic Strategies LLC raised its position in CytomX Therapeutics by 96.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 40,309 shares in the last quarter. Finally, US Bancorp DE purchased a new stake in shares of CytomX Therapeutics in the 3rd quarter worth $40,000. Institutional investors own 67.77% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a research note on Tuesday, January 7th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $5.77.

CytomX Therapeutics Stock Down 1.3 %

Shares of CTMX stock opened at $0.85 on Friday. The company’s 50 day moving average is $1.04 and its 200 day moving average is $1.16. The firm has a market cap of $66.29 million, a price-to-earnings ratio of 4.98 and a beta of 1.03. CytomX Therapeutics, Inc. has a 52-week low of $0.79 and a 52-week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23. The business had revenue of $33.43 million for the quarter, compared to the consensus estimate of $18.92 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same period last year, the business posted $0.04 EPS. Analysts anticipate that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.